- NCIt
- C39750
Loading cancer entity…
Loading cancer entity…
Clinical trials
303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (64)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03197506 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | active not recruiting | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03115333 |
| DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma |
| active not recruiting |
| N/A |
| 146 |
| ECOG-ACRIN Cancer Research GroupNETWORK |
| 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT02337686 | Pembrolizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | active not recruiting | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05095376 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | active not recruiting | Phase 3 | 265 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | active not recruiting | Phase 1 | 12 | James Markert, MDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04197934 | WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | active not recruiting | Phase 1 | 56 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04555577 | Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma | active not recruiting | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03423628 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | active not recruiting | Phase 1 | 159 | AstraZenecaINDUSTRY | 3 | Jul 17, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04216329 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials